Analysed ESPERION THERAPEUTICS INC (ESPR:NASDAQ) News Sources
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
09-04-2026
yahoo.com
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
02-04-2026
yahoo.com
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
02-04-2026
yahoo.com
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
30-03-2026
yahoo.com
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines
20-03-2026
yahoo.com
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
17-03-2026
yahoo.com
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
16-03-2026
yahoo.com
What is the current price of ESPERION THERAPEUTICS INC (ESPR:NASDAQ)?
The current price of ESPERION THERAPEUTICS INC (ESPR:NASDAQ) is $2.17.
ESPERION THERAPEUTICS INC (ESPR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ESPERION THERAPEUTICS INC (ESPR:NASDAQ) since the previous trading day is $-0.01.
ESPERION THERAPEUTICS INC (ESPR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ESPERION THERAPEUTICS INC (ESPR:NASDAQ) since the previous trading day is -0.4587%.
What is the most recent average sentiment score for ESPERION THERAPEUTICS INC (ESPR:NASDAQ)?
The most recent average sentiment score for ESPERION THERAPEUTICS INC (ESPR:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for ESPERION THERAPEUTICS INC (ESPR:NASDAQ)?
The most recent sentiment for ESPERION THERAPEUTICS INC (ESPR:NASDAQ) is .
SEC-8K** Filing Available For ESPERION THERAPEUTICS INC (ESPR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.